human vascular endothelial growth factor 165  (R&D Systems)

Journal: Journal of Translational Medicine

Article Title: The ANGPTL3-integrin α5 axis drives retinal vascular leakage in diabetic retinopathy

doi: 10.1186/s12967-026-07710-4

Figure Lengend Snippet: ANGPTL3 knockout preserves retinal endothelial barrier function by upregulating tight junction proteins. ( A ) Representative TEM images showing tight junction structures in retinal capillary endothelial cells of control, diabetic, and Angptl3 knockout mice. ( B ) Immunofluorescence staining of retinal sections for tight junction proteins ZO-1 and VE-cadherin. Scale bars = 10 μm. ( C and D ) Quantification of ZO-1 and VE-cadherin fluorescence intensity from ( B ). ( E ) Proliferation assay of HUVECs treated with recombinant human ANGPTL3. ( F ) Western blot analysis of ZO-1 and VE-cadherin protein levels in HUVECs following ANGPTL3 treatment. ( G - H ) Quantification of protein expression from ( F ). * P < 0.05, ** P < 0.01

Article Snippet: The cells were equilibrated in ECM containing 1% FBS (Gibco, Cat# 26140079) for 12 h before treatment with recombinant ANGPTL3 (0.25, 0.50, 0.75 μg/mL) or recombinant vascular endothelial growth factor (VEGFA; 50 ng/mL, R&D Systems, Cat# 293-VE/CF) as a positive control.

Techniques: Knock-Out, Control, Immunofluorescence, Staining, Fluorescence, Proliferation Assay, Recombinant, Western Blot, Expressing